Decisions 20th January 2105


At the meeting on the 20th January 2015 the following decisions / changes to the formulary were agreed

New Drug Requests

Approved

Umeclidinium (Incruse Ellipta) (TLS Blue)

  • Approved for COPD maintenance.

Olodaterol (Striverdi Respimat) (TLS Blue)

  • Approved for COPD maintenance.

Beclometasone and formoterol (Fostair pMDI) (TLS Green)

  • Approved for COPD maintenance.  Licence extension for use in COPD.  

Tiotropium (Respimat) (TLS Amber specialist recommendation, no SCP)

  • Approved for use in asthma for those severe patients not controlled at step 4.

Progesterone (Cyclogest) pessaries (TLS Red)

  • Approved for use in IVF patients and threatened pre-term labour.

 

More information required

Progesterone (Cyclogest) pessaries

  • Not approved for use in recurrent miscarraige - await imminent results of the PROMISE trial.

Not approved

Tacrolimus mouthwash

  • Not approved for inclusion onto the formulary due to a lack of evidence in this cohort.  

Shared Care Protocols/TLS Change in Status

Eplerenone

  • Agreed to change to amber (specialist recommendation, no SCP) to enable primary care prescribers to initiate if a specialist has recommended treatment.

Ivabradine

  • To remain as amber 3 months as the NICE TA267 states that ‘Ivabradine should be initiated by a heart failure specialist with access to a multidisciplinary heart failure team. Dose titration and monitoring should be carried out by a heart failure specialist or in primary care by either a GP with a special interest in heart failure or a heart failure specialist nurse.’ 

Lisdexamfetamine (adults)

  • Agreed to change to amber 3 months once a SCP has been developed and approved.

 

Other decisions:


Indacaterol and glycopyrronium (Ultibro Breezehaler)

  • Now available therefore can be added to the formulary for COPD as per December 2013 decision.

 

Last updated by: on 24-03-2015 10:17